APMD

Apnimed Inc

23.80

Sep 21 • 11:14 AM ET -5.20 (-17.93%)

Healthcare Biotechnology USA Small NASD

Today, 11:02 AMNo clear catalyst identified for Apnimed 17% drop in morning trading

Peers: OLMA CGEM ANRO IVA SVRA JANX REPL LXRX AXSM JAZZ

| Held by: IWM IWO VTI IWN IWC VXF VTWO RSSL IBRN JDOC

Scroll to Statements

Index	-
Market Cap	990.81M
Enterprise Value	1.14B
Income	-
Sales	-
Book/sh	-4.23
Cash/sh	4.15
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	-
IPO	Jul 31, 2026

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	-
P/C	5.73
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	5.06
Current Ratio	5.06
Debt/Eq	1.15
LT Debt/Eq	1.15
Option/Short	No / Yes

EPS (ttm)	-
EPS next Y	-
EPS next Q	-0.64
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	-69.75% -
Sales past 3/5Y	237.57% -
EPS Y/Y TTM	-
Sales Y/Y TTM	-
EPS Q/Q	-
Sales Q/Q	-
Earnings	Sep 08 AMC
EPS/Sales Surpr.	905.42% -

Insider Own	6.80%
Insider Trans	12.97%
Inst Own	17.96%
Inst Trans	24.31%
ROA	-
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-12.85%
SMA50	-14.00%
SMA200	-14.00%
Trades

Shs Outstand	41.63M
Shs Float	38.80M
Short Float	1.46%
Short Ratio	1.06
Short Interest	0.56M
52W High	35.29 -32.56%
52W Low	16.12 47.64%
Volatility	7.78% 9.26%
ATR (14)	3.00
RSI (14)	41.90
Beta	-
Rel Volume	1.27
Avg Volume	531.39K
Volume	205,401

Perf Week	-6.85%
Perf Month	-16.64%
Perf Quarter	-
Perf Half Y	-
Perf YTD	8.18%
Perf Year	-
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	50.33
Prev Close	29.00
Price	23.80
Change %	-17.93%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-25-26	Initiated	Evercore ISI	Outperform
Aug-25-26	Initiated	Cantor Fitzgerald	Overweight	$60
Aug-25-26	Initiated	BofA Securities	Buy	$41

Sep-08-26 04:39PM	Apnimed Reports Second Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
Sep-04-26 04:01PM	Apnimed, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-26-26 11:13AM	Moderna Stock Carries A Market Value Its Revenue Does Not Support (Trefis) +8.07%
Aug-25-26 12:12PM	Apnimed shares surge on bullish BofA initiation (Proactive) +6.79%
08:14AM	Nasdaq rises as Wall Street gets relief from falling yields (Proactive)
03:01PM	Loading…
Aug-24-26 03:01PM	Moderna Stock Had A Readout Waiting In Plain Sight (Trefis) -8.56%
Aug-20-26 02:21PM	Moderna's Melanoma Result Landed On A Market Positioned The Other Way (Trefis) -10.86%
Aug-03-26 04:35PM	Apnimed Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)

Apnimed, Inc. operates as a clinical-stage company. It engages in the discovery, development, and commercialization of oral therapies for sleep-related breathing diseases. The company was founded by Lawrence G. Miller, Barry Wohl and Luigi Taranto Montemurro in 2017 and is headquartered in Cambridge, MA.

CEO & DirectorMr. Kevin Robert Lind

M.P.H.Dr. Lawrence G. Miller M.D.

President & COOMr. Dennis Patrick Molnar M.B.A.

Co-Founder & Chief Scientific OfficerDr. Luigi Taranto Montemurro M.D.

Chief Financial OfficerMr. Michael B. Kelly

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Morningside Venture Investment	10% Owner	Aug 03 '26	Buy	16.00	312,500	5,000,000	7,152,713	Aug 05 04:18 PM
SEKHRI PAUL J	Director	Aug 03 '26	Buy	16.00	12,500	200,000	12,500	Aug 03 04:01 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

APMD

Apnimed Inc

Upgrade your Finviz experience